Macular disease - AMD

The Australian eyecare sector is challenging the idea that vision loss with age is inevitable. This, combined with cutting-edge research...

ZEISS has completed the acquisition of D.O.R.C. (Dutch Ophthalmic Research Center) that includes the EVA NEXUS platform, one of the...

A single-dose gene therapy for neovascular age-related macular degeneration (nAMD) is now in Phase 3 clinical trials and, if approved,...

RANZCO’s Referral Pathway for Age-Related Macular Degeneration (AMD) Management has been updated as Australia gears up for the first approved...

A UNSW-developed molecule that could be administered via an eye drop for neovascular age-related macular degeneration (nAMD) is being commercialised...

  Bayer’s high dose aflibercept 8 mg – now approved in the European Union and US – has been labelled...

  At the completion of this CPD activity, optometrists will understand the clinical utility of optical coherence tomography angiography (OCT-A),...

Bayer’s higher dose aflibercept 8 mg with extended treatment intervals is set for approval in the European Union (EU) for...

  Whether ophthalmologists are scanning a three-month-old or elderly patient, the ability of Optos ultra-widefield imaging devices to capture 200°...

Apellis Pharmaceuticals has responded to “positive” 24-month data for its pioneering geographic atrophy (GA) therapy published in The Lancet, demonstrating...